找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Hepatobiliary Cancers: An Interdisciplinary Approach; Nima Rezaei Book 2023 The Editor(s) (if applicable) and The Author(s), under exclusi

[復(fù)制鏈接]
樓主: 鳴叫大步走
31#
發(fā)表于 2025-3-26 21:52:43 | 只看該作者
32#
發(fā)表于 2025-3-27 02:25:47 | 只看該作者
33#
發(fā)表于 2025-3-27 08:44:02 | 只看該作者
Liver Cancer and the Curative Potential of Nanomedicine,the diagnosis occurs frequently at a late stage, where treatment options are limited. Immunotherapy based on targeting checkpoint inhibitors, which unleashes the break of antitumor immunity, works only for a minority of patients. This might partly be owed to the tolerogenic function of the liver. Na
34#
發(fā)表于 2025-3-27 13:02:52 | 只看該作者
35#
發(fā)表于 2025-3-27 16:58:43 | 只看該作者
Drug Resistance in Hepatocellular Carcinoma,e acquired drug resistance increasingly affects the management of HCC patients. Researchers have focused on drug resistance for many years and identified complex regulatory networks involved in this issue. In this chapter, the significant research progress regarding mechanisms underlying HCC drug re
36#
發(fā)表于 2025-3-27 19:27:47 | 只看該作者
Liver Stereotactic Body Radiotherapy (SBRT),organs. In addition, these patients have had worse tumor outcomes when new immunotherapies have been tested in clinical trials, together suggesting there is something especially immunosuppressive about the liver tissue. Initial preclinical and translational studies have brought some light into this
37#
發(fā)表于 2025-3-28 00:17:22 | 只看該作者
38#
發(fā)表于 2025-3-28 02:40:07 | 只看該作者
39#
發(fā)表于 2025-3-28 09:16:34 | 只看該作者
40#
發(fā)表于 2025-3-28 12:43:51 | 只看該作者
Liver Cancer: Interdisciplinary Approach,nvolving multiple signaling pathways such as VEGFR, EGFR, Raf/MEK/ERK, PI3K/AKT, and Wnt. Chronic hepatitis B virus infection is the most common cause. Combining the high-risk factors, imaging features and serological molecular markers of liver cancer, biopsy or surgical resection of liver space-occ
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點評 投稿經(jīng)驗總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機(jī)版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-12 19:55
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
彰化县| 渭源县| 焦作市| 泾阳县| 西峡县| 方城县| 大冶市| 六枝特区| 淮安市| 宜君县| 德惠市| 西峡县| 东乡族自治县| 天水市| 措美县| 电白县| 门头沟区| 张掖市| 贵阳市| 德保县| 林州市| 馆陶县| 孝昌县| 佛山市| 满城县| 甘南县| 西峡县| 长汀县| 临桂县| 柯坪县| 云林县| 西贡区| 阿克陶县| 滦平县| 天峻县| 股票| 娄烦县| 图木舒克市| 清苑县| 绵竹市| 阳信县|